Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder in which androgen excess plays a central pathogenic role, driving both reproductive and metabolic dysfunction. Hyperandrogenism not only contributes to classic clinical features such as hirsutism, acne, and alopecia, but also disrupts follicular development, ovulation, and insulin signalling. Traditional treatment approaches have focused on symptom control rather than underlying mechanisms. However, growing insights into androgen biosynthesis, receptor signalling, and tissue-specific androgen action have led to significant advances in targeted therapeutic strategies. These developments offer new opportunities for more precise and effective management of PCOS.
Role of Androgens in the Pathophysiology of PCOS
Androgens are essential for normal ovarian function at physiological levels, but in PCOS, their excess exerts deleterious effects. Increased androgen production primarily arises from ovarian theca cells, with contributions from adrenal sources. Hyperandrogenism disrupts follicular maturation by impairing granulosa cell function and follicle-stimulating hormone (FSH) responsiveness. Additionally, elevated androgens exacerbate insulin resistance, creating a self-perpetuating cycle that amplifies both metabolic and reproductive abnormalities.
Molecular Pathways Involved in Androgen Excess
Recent research has elucidated key molecular mechanisms underlying androgen overproduction in PCOS. Dysregulation of steroidogenic enzymes, including cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1), enhances androgen biosynthesis. Altered luteinising hormone (LH) signalling further stimulates theca cell androgen secretion. Advances in genomic and proteomic studies have also highlighted aberrant insulin and insulin-like growth factor (IGF) signalling pathways that synergistically promote androgen excess at the ovarian level.
Targeting the Androgen Receptor: Emerging Therapies
Therapeutic strategies aimed at inhibiting the androgen receptor have garnered increasing attention. Nonsteroidal antiandrogens, such as flutamide, bicalutamide, and newer agents like enzalutamide, act by competitively blocking the binding of androgens to the AR. These drugs effectively reduce androgenic symptoms, especially hirsutism. However, concerns regarding hepatotoxicity and other side effects have limited the widespread use of some of these agents.
Recent research has focused on the development of selective androgen receptor modulators (SARMs), which aim to provide the therapeutic benefits of AR inhibition with improved safety profiles. These modulators exhibit tissue-specific actions, thereby minimising systemic adverse effects. Additionally, combination therapies involving AR antagonists and insulin sensitisers are being explored to address both hyperandrogenism and metabolic abnormalities in PCOS.
Inhibition of 5α-Reductase
The enzyme 5α-reductase catalyses the irreversible conversion of testosterone to DHT, a more potent androgen that plays a significant role in the development of clinical hyperandrogenism. 5α-reductase inhibitors, such as finasteride (type II inhibitor) and dutasteride (dual type I and II inhibitor), have shown efficacy in reducing DHT levels and improving symptoms like hirsutism and acne.
Finasteride, in particular, has been studied extensively in PCOS patients and has demonstrated significant reductions in hair growth over time with relatively few side effects. Dutasteride, with broader isoenzyme inhibition, may offer enhanced efficacy, although its use in women is still under investigation due to limited safety data.
Molecular Pathways Involved in Androgen Excess
Recent research has elucidated key molecular mechanisms underlying androgen overproduction in PCOS. Dysregulation of steroidogenic enzymes, including cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1), enhances androgen biosynthesis. Altered luteinising hormone (LH) signalling further stimulates theca cell androgen secretion. Advances in genomic and proteomic studies have also highlighted aberrant insulin and insulin-like growth factor (IGF) signalling pathways that synergistically promote androgen excess at the ovarian level.
Pharmacological Targeting of Androgen Production
Therapeutic strategies aimed at reducing androgen synthesis remain central to PCOS management. Combined oral contraceptives suppress LH secretion and decrease ovarian androgen production while increasing sex hormone–binding globulin (SHBG) levels, thereby reducing free androgen concentrations. Newer approaches include selective steroidogenesis inhibitors that target key enzymes involved in androgen biosynthesis, offering the potential for more targeted suppression with fewer systemic side effects.
Androgen Receptor Antagonism
Blocking androgen action at the receptor level represents another important therapeutic avenue. Anti-androgen agents such as spironolactone, flutamide, and cyproterone acetate inhibit androgen receptor binding, reducing androgen-mediated effects on target tissues. Emerging research is exploring selective androgen receptor modulators (SARMs) and tissue-specific antagonists, which may provide clinical benefits while minimising adverse effects associated with conventional anti-androgens.
Targeting Androgen–Insulin Interactions
The close interplay between insulin resistance and androgen excess has prompted interest in therapies that simultaneously address both pathways. Insulin-sensitising agents, including metformin and newer incretin-based therapies, indirectly reduce androgen levels by lowering insulin-mediated stimulation of theca cells. Combination therapies that integrate metabolic and anti-androgenic approaches may represent a more comprehensive strategy for managing PCOS.
Emerging and Novel Therapeutic Approaches
Advances in molecular biology have paved the way for innovative treatment strategies targeting androgen pathways. These include modulators of adrenal androgen production, inhibitors of androgen conversion in peripheral tissues, and gene-based therapies aimed at correcting underlying steroidogenic abnormalities. Although many of these approaches remain experimental, they highlight a shift toward mechanism-driven and personalised treatment paradigms in PCOS.
Clinical Implications and Future Directions
Targeting androgen pathways offers significant potential for improving both reproductive and metabolic outcomes in women with PCOS. Future research should focus on identifying patient subgroups most likely to benefit from specific androgen-targeted therapies, optimising treatment combinations, and evaluating long-term safety. As understanding of androgen biology in PCOS continues to evolve, personalised and pathway-specific interventions may transform the clinical management of this multifaceted disorder.
Lydia, is a Specialist Dietitian at The London Obesity & Endocrine Clinic. She has helped many patients overcome weight management barriers. ©Simplyweight
Top obesity clinic in Chennai
